Biological agents targeting interleukin-13 for atopic dermatitis.

IF 4 3区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Expert Opinion on Biological Therapy Pub Date : 2022-05-01 Epub Date: 2022-02-06 DOI:10.1080/14712598.2022.2035356

Andrea Chiricozzi, Niccolò Gori, Martina Maurelli, Paolo Gisondi, Giacomo Caldarola, Clara De Simone, Ketty Peris, Giampiero Girolomoni

{"title":"Biological agents targeting interleukin-13 for atopic dermatitis.","authors":"Andrea Chiricozzi, Niccolò Gori, Martina Maurelli, Paolo Gisondi, Giacomo Caldarola, Clara De Simone, Ketty Peris, Giampiero Girolomoni","doi":"10.1080/14712598.2022.2035356","DOIUrl":null,"url":null,"abstract":"Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease that is pathogenically driven by type-2 inflammation. Interleukin-13 (IL-13) plays a central role in AD pathogenesis, as confirmed by the clinical efficacy of agents that selectively block IL-13, although their therapeutic value and place-in-therapy are incompletely defined.Areas covered: This review article aimed to describe preclinical and clinical data regarding selective IL-13 inhibitors investigated in AD. In particular, we discuss the clinical outcomes obtained with lebrikizumab and tralokinumab, which are in a more advanced phase of development.Expert opinion: Biological agents that neutralize IL-13 have demonstrated clinical benefits in treating AD with excellent safety profiles. Robust clinical evidence exists in support of tralokinumab, which underwent phase III trials, met the predefined primary endpoints, and is approaching the market. In contrast, clinical trial testing for lebrikizumab needs to be completed to fully assess its therapeutic potential.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"651-659"},"PeriodicalIF":4.0000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Biological Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14712598.2022.2035356","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/2/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 5

Abstract

Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease that is pathogenically driven by type-2 inflammation. Interleukin-13 (IL-13) plays a central role in AD pathogenesis, as confirmed by the clinical efficacy of agents that selectively block IL-13, although their therapeutic value and place-in-therapy are incompletely defined.

Areas covered: This review article aimed to describe preclinical and clinical data regarding selective IL-13 inhibitors investigated in AD. In particular, we discuss the clinical outcomes obtained with lebrikizumab and tralokinumab, which are in a more advanced phase of development.

Expert opinion: Biological agents that neutralize IL-13 have demonstrated clinical benefits in treating AD with excellent safety profiles. Robust clinical evidence exists in support of tralokinumab, which underwent phase III trials, met the predefined primary endpoints, and is approaching the market. In contrast, clinical trial testing for lebrikizumab needs to be completed to fully assess its therapeutic potential.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

靶向白介素-13的生物制剂治疗特应性皮炎。

特应性皮炎(AD)是一种由2型炎症引起的慢性炎症性皮肤病。白细胞介素-13 (IL-13)在阿尔茨海默病的发病机制中起着核心作用，选择性阻断IL-13的药物的临床疗效证实了这一点，尽管它们的治疗价值和治疗位置尚未完全确定。涵盖领域:这篇综述文章旨在描述关于选择性IL-13抑制剂在AD研究中的临床前和临床数据。特别地，我们讨论了lebrikizumab和tralokinumab的临床结果，它们处于更高级的开发阶段。专家意见:中和IL-13的生物制剂在治疗阿尔茨海默病方面具有良好的安全性。有强有力的临床证据支持tralokinumab，该药物经过了III期试验，达到了预定的主要终点，正在接近市场。相比之下，lebrikizumab的临床试验测试需要完成，以充分评估其治疗潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Opinion on Biological Therapy 医学-生物工程与应用微生物

CiteScore

8.60

自引率

0.00%

发文量

审稿时长

3-8 weeks

期刊介绍： Expert Opinion on Biological Therapy (1471-2598; 1744-7682) is a MEDLINE-indexed, international journal publishing peer-reviewed research across all aspects of biological therapy. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. The audience consists of scientists and managers in the healthcare and biopharmaceutical industries and others closely involved in the development and application of biological therapies for the treatment of human disease. The journal welcomes: Reviews covering therapeutic antibodies and vaccines, peptides and proteins, gene therapies and gene transfer technologies, cell-based therapies and regenerative medicine Drug evaluations reviewing the clinical data on a particular biological agent Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practice Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points.